Author | David Hyman, MD | OncLive

Author | David Hyman, MD

Articles

Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors

July 07, 2014

Video

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.

x